KALRAY
11.5.2023 07:46:32 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris : ALKAL), a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from cloud to edge, is pleased to announce that the IP-CUBE project, led by Kalray, has won the "Technological Maturation and Demonstration of Embedded Artificial Intelligence Solutions" call for projects under the "France Relance 2030 - Future Investments" plan. Kalray's next-generation high-performance, low-power DPU processor is at the heart of the project.
ARTIFICIAL INTELLIGENCE, EDGE COMPUTING, AND SEMICONDUCTORS - MAJOR CHALLENGES FOR THE COMING DECADES
Use cases linked to artificial intelligence (AI) are developing exponentially. Whereas the massive diffusion of AI currently relies heavily on the use of computing resources located in the cloud, there is a growing need for solutions allowing the use of AI in a more reactive, more secure, and less energy hungry way for users. These AI solutions will be deployed in particular in embedded systems as well as local data centers ("edge data centers") that aim to process data closer to where it is generated, as efficiently as possible. This is known as "edge computing", a fast-growing market estimated to be worth several billion Euros1 by 2025 that is comprised of vast areas of the economy such as the telecommunications, new generation of manufacturing, IoT, automotive industry, aerospace, and defense.
However, embedded AI and edge computing require new types of processors and new semiconductor technologies to process and accelerate AI algorithms and meet new technological challenges; high performance, but also low power consumption, low latency, and security.
The IP-CUBE project, led by Kalray, aims to meet these challenges and create the foundations of a French semiconductor ecosystem in the field of edge computing and embedded AI, based on the national leaders in the field, namely Arteris, Kalray, Secure-IC, and Thales.
FINANCING OF STRATEGIC AND SOVEREIGN TECHNOLOGIES
The IP-CUBE project, totaling €36.7M, will directly participate in funding key technology building blocks in this area, particularly Kalray's next-generation Dolomites™ DPU processor for the amount of €10M, Arteris' next-generation NoC (Network-On-Chip), Secure-IC's specialized IP (intellectual property) development for security, and Thales' RISC-V-based low-power component development.
"We are very pleased that the IP-CUBE project has been selected. It will not only allow us to finance a significant part of the development of our 4th generation DPU processor, but also to develop, in collaboration with our partners, the French know-how and technologies in the strategic semiconductor fields around AI applications," said Eric Baissus, CEO of Kalray.
Kalray is the only company in France and Europe to offer DPU (Data Processing Unit) processors, a new type of low-power, high-performance programmable processor, capable of processing data on the fly and multiple applications (AI and others) in parallel, while providing the required security features.
As a pioneer in the field, Kalray has developed a unique expertise and an innovative technology based on its patented MPPA® (Massively Parallel Processor Array) architecture, the cornerstone of its DPU processors and acceleration cards. This technological leadership enables Kalray to offer a serious French and European alternative to the predominantly American or Chinese technology players. At the end of 2022, Kalray announced the signing of a framework contract with a major NASDAQ-listed customer to supply its high-performance DPU cards.
"In the current geopolitical context, the semiconductor industry has become essential, both in terms of production tools and technological know-how for designing processors. France and Europe need production plants, but they also need companies capable of designing the processors that will be manufactured in these plants, and that will be at the heart of tomorrow's markets. We are delighted with the strong support from France through the IP-CUBE project, and the support from Europe through other collaborative projects, such as the EPI (European Processor Initiative), in which Kalray is also participating, to help us achieve our ambition of making Kalray the future European Nvidia," concluded Eric Baissus.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
| ___________________________________ | ||
1 |
McKinsey – AI-related semiconductor market. |
|
NVIDIA: https://blogs.nvidia.com/blog/2019/10/22/what-is-edge-computing/ |
||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom